Search

A solid-phase transfection platform for arrayed CRISPR screens The following sentence should have been included in the introduction: "A previously reported solid-phase reverse transfection method for proteins (Bulkescher I et al i , [1]) was used for the delivery of RNPs for three endogenous genes suggesting the potential of solid-phase reverse transfection for CRISPR/Cas9-based gene editing, despite its low efficiency". Reference 1 Bulkescher R, Starkuviene V, Erfle H (2017) Solid-phase reverse transfection for intracellular delivery of functionally active proteins. [Extracted from the article]

Arrayed CRISPR‐based screens emerge as a powerful alternative to pooled screens making it possible to investigate a wide range of cellular phenotypes that are typically not amenable to pooled screens. Here, we describe a solid‐phase transfection platform that enables CRISPR‐based genetic screens in arrayed format with flexible readouts. We demonstrate efficient gene knockout upon delivery of guide RNAs and Cas9/guide RNA ribonucleoprotein complexes into untransformed and cancer cell lines. In addition, we provide evidence that our platform can be easily adapted to high‐throughput screens and we use this approach to study oncogene addiction in tumor cells. Finally demonstrating that the human primary cells can also be edited using this method, we pave the way for rapid testing of potential targeted therapies. Synopsis: This study presents a solid phase transfection platform that enables CRISPR‐based genetic screens in arrayed format with flexible readouts. Solid phase transfection of gRNAs or RNPs is applicable to a wide variety of cell lines.Solid phase transfection can be easily adapted to high throughput screens.A demonstration that human primary cells can be edited using this platform, indicates the potential of the approach for rapid testing of candidate targeted therapies. [ABSTRACT FROM AUTHOR]